الفهرس 
Material and methodsOnly 14 pages are availabe for public view
 |  | from | 219 |  |  |
| | | from | 219 | | |
Abstract
SUMMARY
SUMMARY
This study was performed to estimate the prevalence of intrahepatic cholestasis in chronic liver diseases and to assess the effect of different drug therapy in improving cholestasis. This study was performed also to assess the safety of these drugs and the compliance of the patients to it 333 patients with CLD enrolled in the study. 103 were selected whom fulfill the criteria of IHC clinically (Jaundice-pruritus-both) with elevated serum bilirubin and direct bilirubin, alkaline phosphatase and y glutamyl transpeptidase.
Mean age of the study groups was 47.3 ± 9.5.
The study group (103) were randomly divided into 3 groups: Group I: Silymarin given to 52 patients.
Group II: UDCA, given to 26 patients.
Group III: Control, 25 patients given placebo.
The epidemiology of IHC showed geo-plotitical and ethnic versatility, but there are no definite ”high risk” attributes within each population (No age is except”, no sex or socioeconomic predilection).
IHC is particularly not associated with pruritus among Egyptians, but commonly associated with jundice. It usually occurs in association with chronic viral hepatitis (33.48%), but the cause is unlcnown in almost
14% of cases.
se 138 to.
SUMMARY
IHC was more frequent in patients with cirrhosis (39.8%), neoplasm (3.88%) and drugs (3.88%) as well as viral causes (3.48%).
52.4% of the patients had jaundice and 7.7% had pruritus. Age, sex and liver stage did not predict the occurrence of IHC.
There were 6 times more patients with jaundice than there were with pruritus (52.4% Vs 7.7%). Other symptoms represented by the patients, steatorrhea, abdominal discomfort, bone pain and bleeding with percent as follows 10.6% and 9.7%, 5.8% and 3.8% respectively.
The present work showed no response of the control group to that means the important of treatment for CLD patients as early as possible.
The statistical difference between the therapy groups and control one were very high significant, but no statistical significant difference
between therapy groups. So there is no scientific ground to perfer either of these two drugs over the other.
.6 1 3 9 ;b.
C’ONCLUSION
CONCLUSION
•IHC must be regarded as a common complication in patients with chronic liver diseases which can be under
estimated when diagnosed only on the basis of overt clinical features.
•IHC being more frequent in advanced diseases.
•Early treatment is necessary as early as possible to lessen
the progress of the disease as well as the need for liver transplantation.
•IHC actually identify a distinct clinico-biochemical syndrome.
nes1408.